Published in
Springer Verlag, PharmacoEconomics, 9(37), p. 1081-1091, 2019
DOI: 10.1007/s40273-019-00779-4
Links
Tools
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Journal article published in 2019 by
Edward Cox 
,
Ros Wade,
Mathilde Peron,
Kristina Charlotte Dietz,
Alison Eastwood,
Stephen Palmer,
Susan Griffin
,
Ros Wade,
Mathilde Peron,
Kristina Charlotte Dietz,
Alison Eastwood,
Stephen Palmer,
Susan Griffin
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 